PEPTIDES·INDEX
72 peptides417 listingsUpdated 5h agoBuild My Stack
Library

ThymogenLongevity

Thymus-derived dipeptide (Glu-Trp) studied for immune modulation; trialed in the US as IM862.

Immune Support
Rating3/5EmergingHuman dataSafety
Compare prices — from $72.00
StatusResearch only
FDA-approvedNO
PrescriptionNO
From$72.00

Overview

Thymogen is the dipeptide L-glutamyl-L-tryptophan (Glu-Trp / EW), isolated from the calf-thymus extract thymalin by Vladimir Khavinson and colleagues and developed into a Russian immunomodulating pharmaceutical. The same molecule was tested in the West as IM862 in US-registered trials: a 25-patient phase II in kidney cancer produced no tumor responses and no drug-related moderate or severe toxicity, and a 202-patient placebo-controlled phase III in AIDS-related Kaposi's sarcoma found it no better than placebo, with a shorter time to progression. Smaller Russian studies report immune effects, and rat work links it to longer maximum lifespan and fewer tumors, but it is not FDA-approved and research-market vials are not the pharmaceutical product.

Related compounds

Super-HLongevityVendor research blend.NAD+LongevityCoenzyme studied for cellular energy and longevity.NAD+ / MOTS-c / 5-Amino-1MQLongevityNAD+ + MOTS-c + 5-Amino-1MQ metabolic & longevity blend.EpitalonLongevityTelomerase peptide studied for sleep and aging.

Sources

Starting references for the library summary. These are not dosing instructions or medical advice.

Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in ratsBiogerontologypubmed.ncbi.nlm.nih.gov/11707921/…Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavityAdvances in Gerontologypubmed.ncbi.nlm.nih.gov/21957588/…Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinomaBritish Journal of Cancerpubmed.ncbi.nlm.nih.gov/15354209/…Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study TeamJournal of Clinical Oncologypubmed.ncbi.nlm.nih.gov/15598977/…Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS PatientsClinicalTrials.govclinicaltrials.gov/study/NCT00002445…

For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.